menu
    • menu
    [{"orgOrder":0,"company":"SciGen","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Oncology","graph2":"Approved FDF","graph3":"SciGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SciGen \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"SciGen \/ DKSH"},{"orgOrder":0,"company":"Avenacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Undisclosed"},{"orgOrder":0,"company":"Lene Bergendal Solberg","sponsor":"Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zoledronic Acid","moa":"Farnesyl diphosphate synthase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Lene Bergendal Solberg","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lene Bergendal Solberg \/ Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Lene Bergendal Solberg \/ Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals for BPH 91

    Menu

    BPH 91

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenacy

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Avenacy

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avenacy Announces Launch of Zoledronic Acid Injection, USP in the U.S. Market

                            Details : Zometa-Generic (zoledronic acid) works by inhibition of bone resorption. It is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma.

                            Product Name : Zometa-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SciGen

                            Singapore arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            SciGen

                            Singapore arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            DKSH Has Successfully Entered into a Strategic Partnership with SciGen in Vietnam

                            Details : DKSH has enetered a strategic partnership with SciGen to supply Zometa (zoledronic acid) to the Vietnamese market. it is indicated for the treatment of Advanced cancers.

                            Product Name : Zometa

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 21, 2023

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : DKSH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lene Bergendal Solberg

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Lene Bergendal Solberg

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase IV

                            Sponsor : Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zoledronate Early to Hip Fracture Patients - Safe and Effective?

                            Details : Zoledronic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hip Fractures.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 27, 2021

                            Lead Product(s) : Zoledronic Acid

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase IV

                            Sponsor : Vestre Viken Hospital Trust | F. Hoffmann-La Roche | Diakonhjemmet Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth